These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 23725164)
1. Histone deacetylases and their inhibitors as potential therapeutic drugs for cholangiocarcinoma - cell line findings. Sriraksa R; Limpaiboon T Asian Pac J Cancer Prev; 2013; 14(4):2503-8. PubMed ID: 23725164 [TBL] [Abstract][Full Text] [Related]
2. Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines. Iwahashi S; Ishibashi H; Utsunomiya T; Morine Y; Ochir TL; Hanaoka J; Mori H; Ikemoto T; Imura S; Shimada M J Med Invest; 2011 Feb; 58(1-2):106-9. PubMed ID: 21372494 [TBL] [Abstract][Full Text] [Related]
3. TACC3 overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors. He JC; Yao W; Wang JM; Schemmer P; Yang Y; Liu Y; Qian YW; Qi WP; Zhang J; Shen Q; Yang T Oncotarget; 2016 Nov; 7(46):75441-75456. PubMed ID: 27705912 [TBL] [Abstract][Full Text] [Related]
4. Synergistic anticancer effects of cisplatin and histone deacetylase inhibitors (SAHA and TSA) on cholangiocarcinoma cell lines. Asgar MA; Senawong G; Sripa B; Senawong T Int J Oncol; 2016 Jan; 48(1):409-20. PubMed ID: 26575528 [TBL] [Abstract][Full Text] [Related]
5. TRAIL in Combination with Subtoxic 5-FU Effectively Inhibit Cell Proliferation and Induce Apoptosis in Cholangiocarcinoma Cells. Sriraksa R; Limpaiboon T Asian Pac J Cancer Prev; 2015; 16(16):6991-6. PubMed ID: 26514480 [TBL] [Abstract][Full Text] [Related]
6. Contribution of Histone Deacetylases in Prognosis and Therapeutic Management of Cholangiocarcinoma. Mastoraki A; Schizas D; Charalampakis N; Naar L; Ioannidi M; Tsilimigras D; Sotiropoulou M; Moris D; Vassiliu P; Felekouras E Mol Diagn Ther; 2020 Apr; 24(2):175-184. PubMed ID: 32125662 [TBL] [Abstract][Full Text] [Related]
7. Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines. Tepsiri N; Chaturat L; Sripa B; Namwat W; Wongkham S; Bhudhisawasdi V; Tassaneeyakul W World J Gastroenterol; 2005 May; 11(18):2748-53. PubMed ID: 15884115 [TBL] [Abstract][Full Text] [Related]
8. β-escin reverses multidrug resistance through inhibition of the GSK3β/β-catenin pathway in cholangiocarcinoma. Huang GL; Shen DY; Cai CF; Zhang QY; Ren HY; Chen QX World J Gastroenterol; 2015 Jan; 21(4):1148-57. PubMed ID: 25632187 [TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase 3 overexpression in human cholangiocarcinoma and promotion of cell growth via apoptosis inhibition. Yin Y; Zhang M; Dorfman RG; Li Y; Zhao Z; Pan Y; Zhou Q; Huang S; Zhao S; Yao Y; Zou X Cell Death Dis; 2017 Jun; 8(6):e2856. PubMed ID: 28569784 [TBL] [Abstract][Full Text] [Related]
10. FOXM1 inhibitor, Siomycin A, synergizes and restores 5-FU cytotoxicity in human cholangiocarcinoma cell lines via targeting thymidylate synthase. Klinhom-On N; Seubwai W; Sawanyawisuth K; Obchoei S; Mahalapbutr P; Wongkham S Life Sci; 2021 Dec; 286():120072. PubMed ID: 34688691 [TBL] [Abstract][Full Text] [Related]
11. Dicoumarol enhances gemcitabine-induced cytotoxicity in high NQO1-expressing cholangiocarcinoma cells. Buranrat B; Prawan A; Kukongviriyapan U; Kongpetch S; Kukongviriyapan V World J Gastroenterol; 2010 May; 16(19):2362-70. PubMed ID: 20480521 [TBL] [Abstract][Full Text] [Related]
12. Diethyldithiocarbamate suppresses an NF-kappaB dependent metastatic pathway in cholangiocarcinoma cells. Srikoon P; Kariya R; Kudo E; Goto H; Vaeteewoottacharn K; Taura M; Wongkham S; Okada S Asian Pac J Cancer Prev; 2013; 14(7):4441-6. PubMed ID: 23992017 [TBL] [Abstract][Full Text] [Related]
14. Luteolin arrests cell cycling, induces apoptosis and inhibits the JAK/STAT3 pathway in human cholangiocarcinoma cells. Aneknan P; Kukongviriyapan V; Prawan A; Kongpetch S; Sripa B; Senggunprai L Asian Pac J Cancer Prev; 2014; 15(12):5071-6. PubMed ID: 24998588 [TBL] [Abstract][Full Text] [Related]
15. Overexpression of membrane metalloendopeptidase inhibits substance P stimulation of cholangiocarcinoma growth. Meng F; DeMorrow S; Venter J; Frampton G; Han Y; Francis H; Standeford H; Avila S; McDaniel K; McMillin M; Afroze S; Guerrier M; Quezada M; Ray D; Kennedy L; Hargrove L; Glaser S; Alpini G Am J Physiol Gastrointest Liver Physiol; 2014 May; 306(9):G759-68. PubMed ID: 24603459 [TBL] [Abstract][Full Text] [Related]
16. Effects of novel HDAC inhibitors on urothelial carcinoma cells. Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501 [TBL] [Abstract][Full Text] [Related]
17. Thymosin β10 as a predictive biomarker of response to 5-fluorouracil chemotherapy in cholangiocarcinoma. Sribenja S; Natthasirikul N; Vaeteewoottacharn K; Sawanyawisuth K; Wongkham C; Jearanaikoon P; Wongkham S Ann Hepatol; 2016; 15(4):577-85. PubMed ID: 27236157 [TBL] [Abstract][Full Text] [Related]
18. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma. Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885 [TBL] [Abstract][Full Text] [Related]
19. Simvastatin and atorvastatin as inhibitors of proliferation and inducers of apoptosis in human cholangiocarcinoma cells. Buranrat B; Senggunprai L; Prawan A; Kukongviriyapan V Life Sci; 2016 May; 153():41-9. PubMed ID: 27098189 [TBL] [Abstract][Full Text] [Related]
20. ALCAM is a Novel Cytoplasmic Membrane Protein in TNF-α Stimulated Invasive Cholangiocarcinoma Cells. Adisakwattana P; Suwandittakul N; Petmitr S; Wongkham S; Sangvanich P; Reamtong O Asian Pac J Cancer Prev; 2015; 16(9):3849-56. PubMed ID: 25987048 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]